Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer.[1] It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1).[2] It was developed by ImmunoGen.
After the huC242 mab binds to the external domain of CanAg, the cantuzumab mertansine-CanAg complex is internalized, and the DM1 molecules are released intracellularly by cleavage of the DM1-huC242 disulfide bonds.[3]
Three phase I clinical studies had reported results by 2003.[4] By 2005, clinical development had been suspended.[5]
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 3.137.171.145